Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
3.830
-0.540 (-12.36%)
At close: Apr 1, 2025, 4:00 PM
4.019
+0.189 (4.93%)
After-hours: Apr 1, 2025, 4:11 PM EDT
Adverum Biotechnologies Revenue
Adverum Biotechnologies had revenue of $1.00M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $1.00M, down -72.22% year-over-year. In the year 2023, Adverum Biotechnologies had annual revenue of $3.60M.
Revenue (ttm)
$1.00M
Revenue Growth
-72.22%
P/S Ratio
74.67
Revenue / Employee
$8,264
Employees
121
Market Cap
79.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ADVM News
- 1 day ago - Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewsWire
- 4 weeks ago - Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD - GlobeNewsWire
- 4 weeks ago - Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients - Seeking Alpha
- 4 months ago - Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - GlobeNewsWire